Drug-Coated Balloon for De Novo Coronary Artery Disease: JACC State-of-the-Art Review.
coronary artery disease
drug-coated balloon
drug-eluting balloon
paclitaxel-coated balloon
paclitaxel-eluting balloon
small-vessel disease
Journal
Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365
Informations de publication
Date de publication:
10 03 2020
10 03 2020
Historique:
received:
03
10
2019
revised:
23
12
2019
accepted:
30
12
2019
entrez:
7
3
2020
pubmed:
7
3
2020
medline:
15
12
2020
Statut:
ppublish
Résumé
Percutaneous coronary intervention with a drug-eluting stent is the most common mode of revascularization for coronary artery disease. However, restenosis rates remain high. Non-stent-based local drug delivery by a drug-coated balloon (DCB) has been investigated, as it leaves no metallic mesh. A DCB consists of a semicompliant balloon coated with antiproliferative agents encapsulated in a polymer matrix, which is released into the wall after inflation and contact with the intima. DCB have demonstrated effectiveness in treating in-stent restenosis. Clinical studies using DCB in de novo coronary artery disease have shown mixed results, with a major benefit in small-vessel disease. Differences in study results are not only due to variations in DCB technology but also to disparity in procedural approach, "leave nothing behind" or "combination therapy," and vessel size. This review focuses on the available evidence from randomized trials and proposes a design for future clinical trials.
Identifiants
pubmed: 32138967
pii: S0735-1097(20)30097-8
doi: 10.1016/j.jacc.2019.12.046
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Paclitaxel
P88XT4IS4D
Sirolimus
W36ZG6FT64
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1061-1073Informations de copyright
Copyright © 2020. Published by Elsevier Inc.